文献速递病毒性肝炎

非肝硬化慢性乙型肝炎患者停用核苷(酸)类似物后乙型肝炎表面抗原丢失的长期发生率与预测因素

Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients.
PubMed 文献 · Clin Microbiol Infect · 2017-12-26

本研究纳入411例非肝硬化慢性乙型肝炎患者(HBeAg阳性148例、HBeAg阴性263例),患者接受拉米夫定(n=110)或恩替卡韦(n=301)治疗,停药后随访至少12个月。结果显示HBeAg阳性患者8年HBsAg丢失率为19.6%,HBeAg阴性患者为33.1%;HBV基因C型和治疗结束时HBsAg水平较低是HBsAg丢失的独立预测因素。作者认为停药后HBsAg丢失率相对较高、肝脏事件发生率较低。

要点

  • HBeAg阳性患者8年HBsAg丢失率为19.6%,HBeAg阴性患者为33.1%。
  • 治疗结束时HBsAg较低者HBsAg丢失率更高:HBeAg阳性者<300 IU/mL时5年为47.3%,HBeAg阴性者<200 IU/mL时8年为69.3%。
  • 5例停药后出现肝炎发作伴失代偿,其中1例再治疗后死亡;48例停药后HBsAg丢失者中2例发生肝细胞癌。

核心结论

  • 非肝硬化慢性乙型肝炎患者停用核苷(酸)类似物后HBsAg丢失率相对较高,肝脏事件发生率较低。

研究设计与样本

  • 研究纳入411例非肝硬化慢性乙型肝炎患者,其中HBeAg阳性148例、HBeAg阴性263例。
  • 患者接受拉米夫定(n=110)或恩替卡韦(n=301)治疗,停药后随访至少12个月。

主要发现

  • HBeAg阳性患者8年累积病毒学复发率、临床复发率和HBsAg丢失率分别为55.6%、47.7%和19.6%。
  • HBeAg阴性患者8年累积病毒学复发率、临床复发率和HBsAg丢失率分别为69.3%、58.9%和33.1%。
  • Cox回归分析显示,HBV基因C型和治疗结束时HBsAg水平较低是HBeAg阳性和阴性患者HBsAg丢失的独立预测因素。
  • 治疗结束时HBsAg<300 IU/mL的HBeAg阳性患者5年HBsAg丢失率为47.3%;治疗结束时HBsAg<200 IU/mL的HBeAg阴性患者8年HBsAg丢失率为69.3%。
  • 5例患者停用核苷(酸)类似物后出现肝炎发作伴失代偿,其中1例再治疗后死亡;48例停药后HBsAg丢失患者中2例发生肝细胞癌。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the long-term incidence and predictors for hepatitis B surface antigen (HBsAg) loss after nucleoside analogue therapy. METHODS: The study included 411 noncirrhotic chronic hepatitis B patients (148 hepatitis B e antigen (HBeAg)-positive and 263 HBeAg-negative patients) who were treated with lamivudine (n = 110) or entecavir (n = 301) with posttreatment follow-up of at least 12 months. RESULTS: In HBeAg-positive patients, the 8-year cumulative rates of virologic relapse, clinical relapse and HBsAg loss were 55.6%, 47.7% and 19.6%, respectively. In HBeAg-negative patients, the rates were 69.3%, 58.9% and 33.1%, respectively. Cox regression analysis showed that hepatitis B virus genotype C and lower end-of-treatment HBsAg levels were independent predictors of HBsAg loss in HBeAg-positive and -negative patients. The 5-year HBsAg loss rate was 47.3% in HBeAg-positive patients with end-of-treatment HBsAg levels <300 IU/mL, while the 8-year HBsAg loss rate was 69.3% in HBeAg-negative patients with end-of-treatment HBsAg levels <200 IU/mL. Five patients experienced hepatitis flares with decompensation after stopping nucleoside analogue therapy, and one died after retreatment. Of the 48 patients who developed off-therapy HBsAg loss, two developed hepatocellular carcinoma. CONCLUSIONS: The rate of HBsAg loss was relatively high and the rate of hepatic events was low in noncirrhotic patients who discontinued nucleoside analogue therapy.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Chen CH, Hung CH, Wang JH, et al. Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients. Clin Microbiol Infect. 2017. PMID: 29288020. doi:10.1016/j.cmi.2017.12.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。